These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27010616)

  • 1. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials.
    Wang J; Logovinsky V; Hendrix SB; Stanworth SH; Perdomo C; Xu L; Dhadda S; Do I; Rabe M; Luthman J; Cummings J; Satlin A
    J Neurol Neurosurg Psychiatry; 2016 Sep; 87(9):993-9. PubMed ID: 27010616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a straightforward and sensitive scale for MCI and early AD clinical trials.
    Huang Y; Ito K; Billing CB; Anziano RJ;
    Alzheimers Dement; 2015 Apr; 11(4):404-14. PubMed ID: 25022537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staging Disease Severity Using the Alzheimer's Disease Composite Score (ADCOMS): A Retrospective Data Analysis.
    Tahami Monfared AA; Houghton K; Zhang Q; Mauskopf J;
    Neurol Ther; 2022 Mar; 11(1):413-434. PubMed ID: 35099758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Clinical Meaningfulness of the Alzheimer's Disease Composite Score (ADCOMS) Tool.
    Tahami Monfared AA; Lenderking WR; Savva Y; Ladd MK; Zhang Q;
    Neurol Ther; 2022 Sep; 11(3):1085-1100. PubMed ID: 35513767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of education on the progression of early- versus late-stage mild cognitive impairment.
    Ye BS; Seo SW; Cho H; Kim SY; Lee JS; Kim EJ; Lee Y; Back JH; Hong CH; Choi SH; Park KW; Ku BD; Moon SY; Kim S; Han SH; Lee JH; Cheong HK; Na DL
    Int Psychogeriatr; 2013 Apr; 25(4):597-606. PubMed ID: 23207181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
    Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K
    Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
    Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
    Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity to change and prediction of global change for the Alzheimer's Questionnaire.
    Malek-Ahmadi M; Chen K; Davis K; Belden CM; Powell J; Jacobson SA; Sabbagh MN
    Alzheimers Res Ther; 2015 Jan; 7():1. PubMed ID: 26584966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hard Test Your Memory. Evaluation of a short cognitive test to detect mild Alzheimer's disease and amnestic mild cognitive impairment.
    Brown JM; Wiggins J; Dong H; Harvey R; Richardson F; Hunter K; Dawson K; Parker RA
    Int J Geriatr Psychiatry; 2014 Mar; 29(3):272-80. PubMed ID: 23929807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild cognitive impairment due to alzheimer disease is less likely under the age of 65.
    Shin S; Kim JH; Cho JH; Kim GS; Choi SA; Lee JH;
    Alzheimer Dis Assoc Disord; 2015; 29(1):26-31. PubMed ID: 24759547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer's disease: a pilot study.
    Buschert VC; Friese U; Teipel SJ; Schneider P; Merensky W; Rujescu D; Möller HJ; Hampel H; Buerger K
    J Alzheimers Dis; 2011; 25(4):679-94. PubMed ID: 21483095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocyte telomere length in mild cognitive impairment and Alzheimer's disease patients.
    Scarabino D; Broggio E; Gambina G; Corbo RM
    Exp Gerontol; 2017 Nov; 98():143-147. PubMed ID: 28827085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE® AD02 in Early Alzheimer's Disease - Prospective Use of Novel Composite Scales.
    Hendrix S; Ellison N; Stanworth S; Tierney L; Mattner F; Schmidt W; Dubois B; Schneeberger A
    J Prev Alzheimers Dis; 2015 Jun; 2(2):91-102. PubMed ID: 26866015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
    Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
    Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADSS: A Composite Score to Detect Disease Progression in Alzheimer's Disease.
    Shan G; Lu X; Li Z; Caldwell JZK; Bernick C; Cummings J
    J Alzheimers Dis Rep; 2024; 8(1):307-316. PubMed ID: 38405343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.